BridgeBio Pharma, Inc.
BBIO
#1437
Rank
$15.516 B
Marketcap
United States
Country
$79.37
Share price
-5.17%
Change (1 day)
28.24%
Change (1 year)
Categories
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for…
Key Metrics
Trailing P/E
—
Forward P/E
2486.35
EPS (TTM)
$-3.56
Forward EPS
$0.03
Price / Book
—
EV / EBITDA
-33.9x
Beta
0.97
Dividend Yield
—
Return on Equity
—
Return on Assets
-26.00%
Debt / Equity
—
Current Ratio
1.23
Gross Margin
94.44%
Operating Margin
-43.94%
Net Profit Margin
-97.03%
Free Cash Flow
$-320,264,128
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 16
-17.69%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$502.076M
Latest Net Income$-724,931,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare BridgeBio Pharma, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
BBIO
No recent news available. Set FINNHUB_API_KEY to enable news.
